Pricing

AMICUS THERAPEUTICS, INC.

0 followers ·
PHILADELPHIA PA
Amicus Therapeutics is based out of Philadelphia. Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The pharmacological chaperone technology involves the use of small molecules to restore biological activity in cells by binding to a misfolded protein caused by a genetic mutation. The company is targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Its lead compound includes Amigal, which is in Phase II clinical trials is used for the treatment of Fabry disease that causes kidney failure, cardiac abnormalities, and neurological complications. The company is also developing AT2101 for the treatment of Gaucher disease, which causes an enlarged liver and spleen, low levels of red blood cells and platelets, bone pain, and fractures; and AT2220 for the treatment of Pompe disease, which causes muscle weakness primarily affecting breathing, mobility, and heart function. The company has a strategic collaboration with Shire Human Genetic Therapies, Inc. to jointly develop pharmacological chaperone compounds for lysosomal storage disorders.Whalewisdom has at least 1 13G filings, and 463 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2023-10-16. The notice included securities offered of Equity

Contact Info

Contact information is taken directly from publicly disclosed SEC filings.

AMICUS THERAPEUTICS, INC.
3675 MARKET STREET
PHILADELPHIA PA    19104

Business Phone: (215) 921-7600
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Recent SEC Filings

Filing Date
4 2024-03-19
4/A 2024-03-15
4/A 2024-03-15
4/A 2024-03-15
4/A 2024-03-15
4/A 2024-03-15
144 2024-03-15
4 2024-03-11
4 2024-03-06
4 2024-03-06